Minute Insight: Mainz Biomed Shows Off New Colorectal Cancer Diagnostic Test Data
The company’s ColoAlert mRNA-based diagnostic has proven similarly efficacious to colonoscopy, while outperforming competing blood/stool-based diagnostics.
You may also be interested in...
Exact Sciences’ next generation of Cologuard, which could be on the market later this year, clearly outperforms its previous.
The Paris-based start-up has picked up a CE mark for the latest generation of its Maestro system, a tool designed to make laparoscopic surgery easier and safer.
The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.